PAR & MPS, page-10

Hi Mozzarc,

Yes - probably something like that, but you'd think it would grate slightly to be selling the raw material at $100 or whatever, and seeing it onsold at $1,500 or whatever.

Do you know if there's been any info provided about Bene's plans (or willingness) to ramp up PPS production, or capex estimates for this? I suppose we just assume that Bene will keep boosting supply to meet whatever increased demand flows from an eventual FDA approval, and pay whatever capex is necessary for the new factories or production lines, etc..

I wonder if a more formal linkup between PAR and Bene has been considered, or a share swap or something along those lines. It might add an extra layer to PAR's IP protection, in case the exclusive supply arrangements were ever held to be anti-competitive.